Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury.

PHASE4CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions
Pain
Interventions
DRUG

Lidocaine

Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.

DRUG

Placebo

Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.

Trial Locations (2)

32601

Shands Hospital, University of Florida, Gainesville

32603

Shands Hospital, Gainesville

All Listed Sponsors
lead

University of Florida

OTHER

NCT02229578 - Lidocaine For Treatment of Post-operative Pain From Donor Sites Following Burn Injury. | Biotech Hunter | Biotech Hunter